Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fractyl Health (GUTS) Cash & Equivalents (2023 - 2025)

Fractyl Health (GUTS) has disclosed Cash & Equivalents for 3 consecutive years, with $77.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 8.23% year-over-year to $77.7 million, compared with a TTM value of $77.7 million through Sep 2025, down 8.23%, and an annual FY2024 reading of $67.5 million, up 103.15% over the prior year.
  • Cash & Equivalents was $77.7 million for Q3 2025 at Fractyl Health, up from $22.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $121.4 million in Q1 2024 and bottomed at $22.3 million in Q2 2025.
  • Average Cash & Equivalents over 3 years is $68.9 million, with a median of $72.6 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents surged 103.15% in 2024, then plummeted 78.24% in 2025.
  • Year by year, Cash & Equivalents stood at $33.2 million in 2023, then skyrocketed by 103.15% to $67.5 million in 2024, then increased by 15.17% to $77.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for GUTS at $77.7 million in Q3 2025, $22.3 million in Q2 2025, and $42.1 million in Q1 2025.